Truly individualized treatment for every round of therapy

Aummune is a pre-clinical cancer therapeutics company developing a breakthrough de novo and rapid process, personalized to a patient's specific disease parameters. The Aummune process is based on a proprietary molecular computation process that designs DNA molecules with specific 3D nanostructures that have high binding affinity and inhibit the growth / induce the death of the biological target with a zero or near-zero off-target effect. Aummune has completed development of a robust, reproducible process and demonstrates successful proof-of-results. A strong patent portfolio has been established, and the company is planning to initiate its clinical program within the next 12 months.


Investing partner / fund: